Drugs / N-Acetylcysteine (NAC)
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01885338 | Jun 2013 → May 2014 | schizophrenia | VA Greater Los Angeles Healthcare System | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07262554 | Nov 2025 → Jun 2026 overdue | periodontitis | Alexandria University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06890507 | Jun 2025 → Apr 2027 expected | nonobstructive coronary artery disease | University of Adelaide | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | N-Acetylcysteine (NAC) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06890507 ↗ |
| Known as | NAC | “The Anti-Anginal Effects of N-Acetylcysteine (NAC) in Patients with Angina and Non-Obstructive Coronary Arteries (ANOCA)” NCT06890507 ↗ |
| Modality | Other / unclassified | “N-acetylcysteine (NAC) is a modified amino acid” NCT01885338 ↗ |
| Route | Oral | “Dosage is 2 capsules by mouth twice daily for 8 weeks.” NCT01885338 ↗ |